Aspire Biopharma Holdings Inc (ASBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Other current assets | 25 | 300 | 0 | 0 | 0 |
| TOTAL | $62 | $343 | $66 | $81 | $253 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 6,601 | 6,525 | 20,136 | 19,901 | 19,641 |
| TOTAL | $6,601 | $6,525 | $20,136 | $19,901 | $19,641 |
| Total Assets | $6,663 | $6,868 | $20,202 | $19,982 | $19,894 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 4,904 | 4,930 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 1,233 | 883 | 634 | 391 | 316 |
| Other current liabilities | N/A | N/A | 1,782 | N/A | N/A |
| TOTAL | $6,573 | $6,240 | $2,633 | $403 | $316 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 6,601 | 6,525 | 20,136 | 19,901 | 19,641 |
| TOTAL | $6,601 | $6,525 | $20,136 | $19,901 | $19,641 |
| Total Liabilities | $13,174 | $12,765 | $22,769 | $20,305 | $19,957 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 194 | 194 | 194 | 225 | 225 |
| Common Shares | 1 | 1 | 1 | 1 | 1 |
| Retained earnings | -15,376 | -14,762 | -13,990 | -11,288 | -10,876 |
| TOTAL | $-6,511 | $-5,897 | $-2,568 | $-322 | $-63 |
| Total Liabilities And Equity | $6,663 | $6,868 | $20,202 | $19,982 | $19,894 |